N/A N=1,539 A Stigma Reduction Intervention at Time of Entry Into Antenatal Care to Improve PMTCT Services in Tanzania
HIV Infections
Primary: HIV Care Engagement (Female HIV-infected Participants Only) — 3; 3 Participants — p=0.963
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=31 Correlation of Changes in PaO2 and ORi in Adult Patients
Hyperoxia
Primary: Sensitivity for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values. — 100 percentage of true positives
Phase 2 N=46 A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Number of Participants and Severity of AEs — 8; 8; 9; 3 Number
Phase 3 N=456 Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria
Malaria
Primary: Crude Cure Rate on Day 14 — 217; 209; 75; 73 Participants
Phase 2 N=35 A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Primary: Objective Response Rate (ORR) — 25.7 percentage of participants
Phase 2 N=30 Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty
Scar Prevention
Primary: Part B: Expert Panel Scar Assessment Score — -3.16; 0.18; 1.45; 2.91 millimeters
Phase 2 N=19 High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients
Cancer
Primary: Change in Dyspnea Numeric Score Between 0 and 10 Minutes — -1.8; -1.8; -0.6; -0.5 score on a scale
N/A N=51 PCI Alternative Using Sustained Exercise
Cardiovascular Disease
Primary: Myocardial Perfusion Reserve — 2.76; 2.47; 2.82; 2.52 Ratio
N/A N=43 Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease
Gastroesophageal Reflux · Laryngopharyngeal Reflux
Primary: Patient-reported Symptom Response to Treatment Measured by the Reflux Symptom Index (RSI) Score — 15.5 score on a scale
N/A N=25 Transcranial Direct Current Stimulation (tDCS) and Intensive Therapy in Aphasia
Aphasia
Primary: Change in Controlled Oral Word Fluency — 3.1 number of words
N/A N=133 ClariFix Rhinitis RCT
Chronic Rhinitis
Primary: rTNSS Responder Rate — 47; 23 Participants
Phase 2 N=223 A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
Radiation Induced Oral Mucositis
Primary: Duration (in Days) of Radiation Induced Severe Oral Mucositis (OM) Per World Health Organization (WHO) Criteria — 8; 1.5; 19 days
Phase 2 N=304 Dose Range Study of CD5789 in Acne Vulgaris
Acne Vulgaris
Primary: Percentage of Participants With Success Rate 1 (SR1) — 29.51; 32.79; 26.67; 32.79 percentage of participants — p=0.096
Phase 2 N=29 Pharmacokinetics of HLD200 in Children and Adolescents With ADHD
Attention-Deficit Hyperactivity Disorder
Primary: PK Parameters for Rate and Extent of Absorption of MPH: Lag Time — 6.3; 3.3 hours
Phase 2 N=244 Memory Aid by Intranasal Insulin in Diabetes (MemAID)
Type 2 Diabetes Mellitus
Primary: Gait Speed Normal Walk (cm/s). — 112.23; 103.42; 121.58; 119.51 cm/s — p=0.025